**Selected for 2026 Doody's Core Titles as an Essential Purchase in Medical/Surgical**
Find the essential information you need to safely administer more than 400 intravenous drugs! The newest edition of a reference trusted for more than 50 years, Elsevier’s 2027 Intravenous Medications is a concise, quick-access guide to complete, accurate drug information. New to this edition are 10-20 monographs of the most recent IV drugs to be approved by the FDA, in addition to updated drug uses, interactions, precautions, alerts, and patient teaching instructions for all current IV drugs. Known as the #1 IV drug handbook on the market, this annual publication is ideal for use in critical care areas, at the nursing station, in the office, and in public health and home care settings.
1. Elsevier’s 2027 Intravenous Medications : A Handbook for Nurses and Health Professionals - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. General Dilution Charts - p. iii 6. HOW TO USE THIS BOOK - p. iii 7. Copyright - p. vi 8. Dedication - p. vii 9. PREFACE - p. ix 10. FORMAT AND CONTENT OF INTRAVENOUS MEDICATIONS - p. xiii 11. KEY TO ABBREVIATIONS - p. xvii 12. IMPORTANT IV THERAPY FACTS - p. xix 13. RESOURCES - p. xxi 14. PREPARATION AND ADMINISTRATION OF INJECTABLE DRUGS - p. xxiii 15. IV Drugs - p. xxvi 16. GENERIC DRUGS: A - p. e1 17. A - p. e1 18. ABATACEPT - p. e1 19. ACETAMINOPHEN - p. 4 20. ACETAZOLAMIDE SODIUM - p. 7 21. ACETYLCYSTEINE INJECTION - p. 8 22. ACYCLOVIR - p. 12 23. ADENOSINE - p. 15 24. ADUCANUMAB - p. 19 25. ALBUMIN (HUMAN) - p. 20 26. ALDESLEUKIN - p. 23 27. ALEMTUZUMAB - p. 29 28. ALLOPURINOL SODIUM - p. 37 29. ALPROSTADIL - p. 40 30. ALTEPLASE - p. 42 31. AMIKACIN SULFATE - p. 49 32. AMINOCAPROIC ACID - p. 52 33. AMINOPHYLLINE - p. 54 34. AMIODARONE HYDROCHLORIDE - p. 60 35. AMISULPRIDE - p. 66 36. AMPHOTERICIN B * ■ AMPHOTERICIN B LIPID-BASED PRODUCTS - p. 68 37. AMPICILLIN SODIUM AND SULBACTAM SODIUM - p. 73 38. ANGIOTENSIN II INJECTION - p. 76 39. ANIDULAFUNGIN - p. 78 40. ANIFROLUMAB - p. 81 41. ANTIHEMOPHILIC FACTOR (HUMAN ■ RECOMBINANT ■ RECOMBINANT [Fc FUSION PROTEIN] ■ RECOMBINANT [PEGYLATED] ■ RECOMBINANT [PEGYLATED-aucl] ■ RECOMBINANT [SINGLE CHAIN] ■ RECOMBINANT [PORCINE SEQUENCE]a) - p. 83 42. ANTIHEMOPHILIC FACTOR ■ VON WILLEBRAND FACTOR COMPLEX (HUMAN) - p. 94 43. ANTITHROMBIN III (HUMAN) - p. 100 44. USUAL DOSE (International units [IU]) - p. 101 45. DOSE ADJUSTMENTS - p. 101 46. DILUTION - p. 101 47. COMPATIBILITY - p. 101 48. RATE OF ADMINISTRATION - p. 102 49. ACTIONS - p. 102 50. INDICATIONS AND USES - p. 102 51. CONTRAINDICATIONS - p. 102 52. PRECAUTIONS - p. 102 53. DRUG/LAB INTERACTIONS - p. 102 54. SIDE EFFECTS - p. 102 55. ANTIDOTE - p. 102 56. ANTITHROMBIN RECOMBINANT - p. 103 57. ANTITHYMOCYTE GLOBULIN (RABBIT) - p. 105 58. ANTIVENIN (LATRODECTUS MACTANS) - p. 108 59. APREPITANT - p. 108.e2 60. ARGATROBAN - p. 110 61. ATEZOLIZUMAB - p. 114 62. ATROPINE SULFATE - p. 121 63. AVELUMAB - p. 123 64. AXATILIMAB - p. 128 65. AZACITIDINE - p. 130 66. AZITHROMYCIN - p. 134 67. AZTREONAM - p. 137 68. GENERIC DRUGS: B - p. e2 69. B - p. e2 70. GENERIC DRUGS: C - p. e3 71. C - p. e3 72. C1 ESTERASE INHIBITOR (HUMAN OR RECOMBINANT) - p. e3 73. CAFFEINE AND SODIUM BENZOATE - p. 198 74. CAFFEINE CITRATE - p. 198.e2 75. CALCITRIOL - p. 200 76. CALCIUM CHLORIDE - p. 203 77. CALCIUM GLUCONATE - p. 205 78. CANGRELOR - p. 208 79. CARBOPLATIN - p. 210 80. CARFILZOMIB - p. 213 81. CASPOFUNGIN ACETATE - p. 213.e10 82. CEFAZOLIN SODIUM - p. 217 83. CEFEPIME AND ENMETAZOBACTAM - p. 219 84. CEFEPIME HYDROCHLORIDE - p. 221 85. CEFIDEROCOL - p. 225 86. CEFOTAXIME SODIUM - p. 228 87. CEFOTETAN DISODIUM - p. 231 88. CEFOXITIN SODIUM - p. 234 89. CEFTAROLINE FOSAMIL - p. 238 90. CEFTAZIDIME - p. 241 91. CEFTAZIDIME/AVIBACTAM - p. 245 92. CEFTOBIPROLE MEDOCARIL - p. 249 93. CEFTOLOZANE/TAZOBACTAM - p. 252 94. CEFTRIAXONE SODIUM - p. 254 95. CEFUROXIME SODIUM - p. 258 96. CEMIPLIMAB-rwlc - p. 261 97. CENTRUROIDES (SCORPION) IMMUNE F(ab’)2 (EQUINE) INJECTION - p. 265 98. CETIRIZINE HYDROCHLORIDE - p. 265.e2 99. CETUXIMAB - p. 266 100. CHLORAMPHENICOL SODIUM SUCCINATE - p. 271 101. CHLOROTHIAZIDE SODIUM - p. 271.e3 102. CHLORPROMAZINE HYDROCHLORIDE - p. 273 103. USUAL DOSE - p. 274 104. PEDIATRIC DOSE - p. 274 105. DOSE ADJUSTMENTS - p. 274 106. DILUTION - p. 274 107. COMPATIBILITY - p. 274 108. RATE OF ADMINISTRATION - p. 274 109. ACTIONS - p. 274 110. INDICATIONS AND USES - p. 275 111. CONTRAINDICATIONS - p. 275 112. PRECAUTIONS - p. 275 113. DRUG/LAB INTERACTIONS - p. 276 114. SIDE EFFECTS - p. 276 115. ANTIDOTE - p. 276 116. CIPROFLOXACIN - p. 277 117. CISPLATIN - p. 283 118. CLEVIDIPINE BUTYRATE - p. 286 119. CLINDAMYCIN PHOSPHATE - p. 288 120. CLOFARABINE - p. 291 121. COAGULATION FACTOR VIIa (RECOMBINANT) RTS - p. 295 122. COAGULATION FACTOR X (HUMAN) - p. 298 123. COAGULATION FACTOR Xa (RECOMBINANT), INACTIVATED-zhzo - p. 301 124. COLISTIMETHATE SODIUM - p. 303 125. CONIVAPTAN HYDROCHLORIDE - p. 306 126. CONJUGATED ESTROGENS - p. 308 127. COPANLISIB - p. 313.e3 128. CORTICORELIN OVINE TRIFLUTATE - p. 313.e7 129. COSIBELIMAB - p. 313.e9 130. COSYNTROPIN - p. 312 131. CRIZANLIZUMAB-tmca INJECTION - p. 314 132. CROTALIDAE IMMUNE F(ab’)2 (EQUINE) - p. 314.e2 133. CYCLOPHOSPHAMIDE - p. 314.e4 134. CYCLOSPORINE - p. 319 135. CYSTEINE HYDROCHLORIDE - p. 323 136. CYTARABINE - p. 327 137. CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) * - p. 329 138. GENERIC DRUGS: D - p. e4 139. D - p. e4 140. DACARBAZINE - p. e4 141. DACTINOMYCIN - p. 333 142. DALBAVANCIN - p. 333.e3 143. DANTROLENE SODIUM - p. 335 144. DAPTOMYCIN - p. 338 145. DARATUMUMAB - p. 343 146. DARBEPOETIN ALFA - p. 343.e6 147. DAUNORUBICIN HYDROCHLORIDE ■ DAUNORUBICIN CITRATE LIPOSOMAL INJECTION - p. 349 148. DEFEROXAMINE MESYLATE - p. 353 149. DEFIBROTIDE - p. 353.e3 150. DELAFLOXACIN - p. 353.e6 151. DENILEUKIN DIFTITOX - p. 357 152. DESMOPRESSIN ACETATE - p. 357.e3 153. DEXAMETHASONE SODIUM PHOSPHATE - p. 360 154. DEXRAZOXANE - p. 365 155. DEXTRAN 1 - p. 368 156. DEXTRAN HIGH MOLECULAR WEIGHT - p. 368.e1 157. DEXTRAN LOW MOLECULAR WEIGHT - p. 370 158. DEXTROSE - p. 371 159. DIAZEPAM - p. 375 160. DIAZOXIDE - p. 378 161. Difelikefalin - p. 378.e2 162. DIGOXIN - p. 379 163. DIGOXIN IMMUNE FAB (OVINE) - p. 385 164. DIHYDROERGOTAMINE MESYLATE - p. 387 165. DILTIAZEM HYDROCHLORIDE - p. 389 166. DIMENHYDRINATE - p. 393 167. DINUTUXIMAB - p. 393.e2 168. DIPHENHYDRAMINE HYDROCHLORIDE - p. 398 169. DIPHTHERIA ANTITOXIN - p. 400 170. DIPYRIDAMOLE - p. 400.e2 171. DOBUTAMINE HYDROCHLORIDE - p. 402 172. DOCETAXEL - p. 405 173. USUAL DOSE - p. 406 174. DOSE ADJUSTMENTS - p. 407 175. DILUTION - p. 408 176. COMPATIBILITY - p. 409 177. RATE OF ADMINISTRATION - p. 409 178. ACTIONS - p. 409 179. INDICATIONS AND USES - p. 410 180. CONTRAINDICATIONS - p. 410 181. PRECAUTIONS - p. 410 182. DRUG/LAB INTERACTIONS - p. 412 183. SIDE EFFECTS - p. 412 184. ANTIDOTE - p. 413 185. Donanemab - p. 413 186. DOPAMINE HYDROCHLORIDE - p. 417 187. DOXAPRAM HYDROCHLORIDE - p. 421 188. DOXERCALCIFEROL - p. 421.e4 189. DOXORUBICIN HYDROCHLORIDE ■ DOXORUBICIN HYDROCHLORIDE LIPOSOMAL INJECTION - p. 424 190. DOXYCYCLINE HYCLATE - p. 431 191. DROPERIDOL - p. 434 192. DURVALUMAB - p. 434.e3 193. GENERIC DRUGS: E - p. e5 194. E - p. e5 195. GENERIC DRUGS: F - p. e6 196. F - p. e6 197. GENERIC DRUGS: G - p. e7 198. G - p. e7 199. GENERIC DRUGS: H - p. e8 200. H - p. e8 201. GENERIC DRUGS: I - p. e9 202. I - p. e9 203. IBALIZUMAB-uiyk - p. e9 204. IBANDRONATE SODIUM - p. 635 205. IBUPROFEN - p. 638 206. IBUPROFEN LYSINE - p. 642 207. IBUTILIDE FUMARATE - p. 644 208. IDARUBICIN HYDROCHLORIDE - p. 646 209. IDARUCIZUMAB - p. 649 210. IDURSULFASE - p. 651 211. IFOSFAMIDE - p. 651.e3 212. ILOPROST - p. 655 213. IMETELSTAT - p. 657 214. IMIGLUCERASE ■ VELAGLUCERASE ALFA - p. 659 215. IMIPENEM-CILASTATIN - p. 659.e4 216. IMIPENEM, CILASTATIN, AND RELEBACTAM - p. 663 217. IMMUNE GLOBULIN INTRAVENOUS - p. 667 218. INDOMETHACIN SODIUM - p. 676 219. INFLIXIMAB ■ INFLIXIMAB-dyyba ■ INFLIXIMAB-abdaa ■ INFLIXIMAB-axxqa ■ INFLIXIMAB-qbtxa - p. 678 220. INSULIN HUMAN ASPART or LISPRO or GLULISINE - p. 685 221. INOTUZUMAB OZOGAMICIN - p. 687 222. INSULIN HUMAN INJECTION (REGULAR) - p. 689.e5 223. INTERFERON ALFA-2b, RECOMBINANT - p. 693 224. IPILIMUMAB - p. 693.e4 225. IRINOTECAN HYDROCHLORIDE ■ IRINOTECAN LIPOSOME INJECTION - p. 693.e10 226. IRON DEXTRAN INJECTION - p. 703 227. IRON SUCROSE - p. 705 228. ISATUXIMAB - p. 709 229. USUAL DOSE - p. 709 230. PEDIATRIC DOSE - p. 709 231. DOSE ADJUSTMENTS - p. 709 232. DILUTION - p. 709 233. COMPATIBILITY - p. 710 234. RATE OF ADMINISTRATION - p. 710 235. ACTIONS - p. 710 236. INDICATIONS AND USES - p. 710 237. CONTRAINDICATIONS - p. 710 238. PRECAUTIONS - p. 710 239. DRUG/LAB INTERACTIONS - p. 710 240. SIDE EFFECTS - p. 710 241. ANTIDOTE - p. 710 242. ISAVUCONAZONIUM SULFATE - p. 710 243. ISOPROTERENOL HYDROCHLORIDE - p. 713 244. IXABEPILONE - p. 717 245. GENERIC DRUGS: K - p. e10 246. K - p. e10 247. GENERIC DRUGS: L - p. e11 248. L - p. e11 249. GENERIC DRUGS: M - p. e12 250. M - p. e12 251. MAGNESIUM SULFATE - p. e12 252. MANNITOL - p. 769 253. MECHLORETHAMINE HYDROCHLORIDE - p. 773 254. MELOXICAM INJECTION - p. 773.e2 255. MEPERIDINE HYDROCHLORIDE - p. 776 256. MEROPENEM - p. 781 257. MEROPENEM AND VABORBACTAM FOR INJECTION - p. 785 258. MESNA - p. 788 259. METHADONE HYDROCHLORIDE - p. 791 260. METHOCARBAMOL - p. 799 261. METHOTREXATE SODIUM - p. 793 262. METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA - p. 805 263. METHYLENE BLUE - p. 805.e5 264. METHYLERGONOVINE MALEATE - p. 805.e8 265. METHYLPREDNISOLONE SODIUM SUCCINATE - p. 807 266. METOCLOPRAMIDE HYDROCHLORIDE - p. 812 267. METOPROLOL TARTRATE - p. 815 268. METRONIDAZOLE HYDROCHLORIDE - p. 818 269. MICAFUNGIN SODIUM - p. 822 270. MILRINONE LACTATE - p. 826 271. MINOCYCLINE HYDROCHLORIDE - p. 829 272. MITOMYCIN - p. 829.e3 273. MITOXANTRONE HYDROCHLORIDE - p. 832 274. MOGAMULIZUMAB-kpkc - p. 835 275. MORPHINE SULFATE - p. 835.e3 276. MOSUNETUZUMAB - p. 840 277. MOXIFLOXACIN HYDROCHLORIDE - p. 846 278. MULTIVITAMIN INFUSION - p. 851 279. USUAL DOSE - p. 852 280. PEDIATRIC DOSE - p. 852 281. DILUTION - p. 852 282. COMPATIBILITY - p. 852 283. RATE OF ADMINISTRATION - p. 853 284. ACTIONS - p. 853 285. INDICATIONS AND USES - p. 853 286. CONTRAINDICATIONS - p. 853 287. PRECAUTIONS - p. 853 288. DRUG/LAB INTERACTIONS - p. 854 289. SIDE EFFECTS - p. 854 290. ANTIDOTE - p. 854 291. MYCOPHENOLATE MOFETIL HYDROCHLORIDE - p. 854 292. GENERIC DRUGS: N - p. e13 293. N - p. e13 294. GENERIC DRUGS: O - p. e14 295. O - p. e14 296. GENERIC DRUGS: P - p. e15 297. P - p. e15 298. PACLITAXEL ■ PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) - p. e15 299. PALIFERMIN - p. 938 300. PALONOSETRON - p. 941 301. PAMIDRONATE DISODIUM - p. 943 302. PANITUMUMAB - p. 947 303. PANTOPRAZOLE SODIUM - p. 951 304. PAPAVERINE HYDROCHLORIDE - p. 954 305. PARICALCITOL - p. 956 306. PEGASPARGASE ■ ASPARAGINASE Erwinia chrysanthemi - p. 959 307. PEGLOTICASE - p. 959.e5 308. PEMBROLIZUMAB - p. 962 309. PEMETREXED - p. 970 310. PENICILLIN G AQUEOUS - p. 974 311. PENTAMIDINE ISETHIONATE - p. 978 312. PENTETATE CALCIUM TRISODIUM INJECTION ■ PENTETATE ZINC TRISODIUM INJECTION - p. 979 313. PENTOBARBITAL SODIUM - p. 979.e4 314. PENTOSTATIN - p. 981 315. PERAMIVIR - p. 984 316. PERTUZUMAB - p. 986 317. PHENOBARBITAL SODIUM - p. 991 318. PHENTOLAMINE MESYLATE - p. 993 319. PHENYLEPHRINE HYDROCHLORIDE - p. 993.e2 320. PHENYTOIN SODIUM - p. 995 321. PHOSPHATE - p. 1000 322. PHYSOSTIGMINE SALICYLATE - p. 1001 323. PHYTONADIONE - p. 1003 324. PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM - p. 1005 325. PLASMA PROTEIN FRACTION - p. 1009 326. POLATUZUMAB VEDOTIN-piiq - p. 1009.e2 327. USUAL DOSE - p. 1010 328. DOSE ADJUSTMENTS - p. 1010 329. DILUTION - p. 1010 330. COMPATIBILITY - p. 1012 331. RATE OF ADMINISTRATION - p. 1012 332. ACTIONS - p. 1012 333. INDICATIONS AND USES - p. 1012 334. CONTRAINDICATIONS - p. 1012 335. PRECAUTIONS - p. 1012 336. DRUG/LAB INTERACTIONS - p. 1014 337. SIDE EFFECTS - p. 1014 338. ANTIDOTE - p. 1014 339. POOLED PLASMA (HUMAN) - p. 1014 340. PORFIMER SODIUM - p. 1014.e3 341. POSACONAZOLE - p. 1019 342. POTASSIUM ACETATE AND POTASSIUM CHLORIDE - p. 1023 343. PRALATREXATE - p. 1027 344. PRALIDOXIME CHLORIDE - p. 1031 345. PROCAINAMIDE HYDROCHLORIDE - p. 1031.e3 346. PROCHLORPERAZINE EDISYLATE - p. 1034 347. PROMETHAZINE HYDROCHLORIDE - p. 1037 348. PROPOFOL INJECTION - p. 1040 349. PROPRANOLOL HYDROCHLORIDE - p. 1045 350. PROTAMINE SULFATE - p. 1049 351. PROTEIN AMINO ACIDS, DEXTROSE, FAT EMULSION, AND ELECTROLYTES - p. 1051 352. PROTEIN (AMINO ACID) PRODUCTS - p. 1056 353. PROTEIN C CONCENTRATE (HUMAN) - p. 1056.e5 354. PROTHROMBIN COMPLEX CONCENTRATE (HUMAN) - p. 1056.e8 355. PYRIDOSTIGMINE BROMIDE - p. 1059 356. PYRIDOXINE HYDROCHLORIDE - p. 1059.e2 357. GENERIC DRUGS: R - p. e17 358. R - p. e17 359. GENERIC DRUGS: S - p. e18 360. S - p. e18 361. GENERIC DRUGS: T - p. e19 362. T - p. e19 363. GENERIC DRUGS: V - p. e20 364. V - p. e20 365. GENERIC DRUGS: Z - p. e21 366. Z - p. e21 367. Appendix A. Recommendations for the Safe Use and Handling of Cytotoxic Drugs - p. 1253.e1 368. Appendix B. FDA Pregnancy Categories - p. 1253.e2 369. Appendix C. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) - p. 1253.e3 370. Appendix D. Information for Patients Receiving Immunosuppressive Agents - p. 1253.e4 371. Appendix E. Recently Approved Drugs - p. 1253.e5 372. Index - p. 1254 373. Solution Compatibility Chart - p. ES3
**Selected for 2026 Doody's Core Titles as an Essential Purchase in Medical/Surgical**
Find the essential information you need to safely administer more than 400 intravenous drugs! The newest edition of a reference trusted for more than 50 years, Elsevier’s 2027 Intravenous Medications is a concise, quick-access guide to complete, accurate drug information. New to this edition are 10-20 monographs of the most recent IV drugs to be approved by the FDA, in addition to updated drug uses, interactions, precautions, alerts, and patient teaching instructions for all current IV drugs. Known as the #1 IV drug handbook on the market, this annual publication is ideal for use in critical care areas, at the nursing station, in the office, and in public health and home care settings.
1. Elsevier’s 2027 Intravenous Medications : A Handbook for Nurses and Health Professionals - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. General Dilution Charts - p. iii 6. HOW TO USE THIS BOOK - p. iii 7. Copyright - p. vi 8. Dedication - p. vii 9. PREFACE - p. ix 10. FORMAT AND CONTENT OF INTRAVENOUS MEDICATIONS - p. xiii 11. KEY TO ABBREVIATIONS - p. xvii 12. IMPORTANT IV THERAPY FACTS - p. xix 13. RESOURCES - p. xxi 14. PREPARATION AND ADMINISTRATION OF INJECTABLE DRUGS - p. xxiii 15. IV Drugs - p. xxvi 16. GENERIC DRUGS: A - p. e1 17. A - p. e1 18. ABATACEPT - p. e1 19. ACETAMINOPHEN - p. 4 20. ACETAZOLAMIDE SODIUM - p. 7 21. ACETYLCYSTEINE INJECTION - p. 8 22. ACYCLOVIR - p. 12 23. ADENOSINE - p. 15 24. ADUCANUMAB - p. 19 25. ALBUMIN (HUMAN) - p. 20 26. ALDESLEUKIN - p. 23 27. ALEMTUZUMAB - p. 29 28. ALLOPURINOL SODIUM - p. 37 29. ALPROSTADIL - p. 40 30. ALTEPLASE - p. 42 31. AMIKACIN SULFATE - p. 49 32. AMINOCAPROIC ACID - p. 52 33. AMINOPHYLLINE - p. 54 34. AMIODARONE HYDROCHLORIDE - p. 60 35. AMISULPRIDE - p. 66 36. AMPHOTERICIN B * ■ AMPHOTERICIN B LIPID-BASED PRODUCTS - p. 68 37. AMPICILLIN SODIUM AND SULBACTAM SODIUM - p. 73 38. ANGIOTENSIN II INJECTION - p. 76 39. ANIDULAFUNGIN - p. 78 40. ANIFROLUMAB - p. 81 41. ANTIHEMOPHILIC FACTOR (HUMAN ■ RECOMBINANT ■ RECOMBINANT [Fc FUSION PROTEIN] ■ RECOMBINANT [PEGYLATED] ■ RECOMBINANT [PEGYLATED-aucl] ■ RECOMBINANT [SINGLE CHAIN] ■ RECOMBINANT [PORCINE SEQUENCE]a) - p. 83 42. ANTIHEMOPHILIC FACTOR ■ VON WILLEBRAND FACTOR COMPLEX (HUMAN) - p. 94 43. ANTITHROMBIN III (HUMAN) - p. 100 44. USUAL DOSE (International units [IU]) - p. 101 45. DOSE ADJUSTMENTS - p. 101 46. DILUTION - p. 101 47. COMPATIBILITY - p. 101 48. RATE OF ADMINISTRATION - p. 102 49. ACTIONS - p. 102 50. INDICATIONS AND USES - p. 102 51. CONTRAINDICATIONS - p. 102 52. PRECAUTIONS - p. 102 53. DRUG/LAB INTERACTIONS - p. 102 54. SIDE EFFECTS - p. 102 55. ANTIDOTE - p. 102 56. ANTITHROMBIN RECOMBINANT - p. 103 57. ANTITHYMOCYTE GLOBULIN (RABBIT) - p. 105 58. ANTIVENIN (LATRODECTUS MACTANS) - p. 108 59. APREPITANT - p. 108.e2 60. ARGATROBAN - p. 110 61. ATEZOLIZUMAB - p. 114 62. ATROPINE SULFATE - p. 121 63. AVELUMAB - p. 123 64. AXATILIMAB - p. 128 65. AZACITIDINE - p. 130 66. AZITHROMYCIN - p. 134 67. AZTREONAM - p. 137 68. GENERIC DRUGS: B - p. e2 69. B - p. e2 70. GENERIC DRUGS: C - p. e3 71. C - p. e3 72. C1 ESTERASE INHIBITOR (HUMAN OR RECOMBINANT) - p. e3 73. CAFFEINE AND SODIUM BENZOATE - p. 198 74. CAFFEINE CITRATE - p. 198.e2 75. CALCITRIOL - p. 200 76. CALCIUM CHLORIDE - p. 203 77. CALCIUM GLUCONATE - p. 205 78. CANGRELOR - p. 208 79. CARBOPLATIN - p. 210 80. CARFILZOMIB - p. 213 81. CASPOFUNGIN ACETATE - p. 213.e10 82. CEFAZOLIN SODIUM - p. 217 83. CEFEPIME AND ENMETAZOBACTAM - p. 219 84. CEFEPIME HYDROCHLORIDE - p. 221 85. CEFIDEROCOL - p. 225 86. CEFOTAXIME SODIUM - p. 228 87. CEFOTETAN DISODIUM - p. 231 88. CEFOXITIN SODIUM - p. 234 89. CEFTAROLINE FOSAMIL - p. 238 90. CEFTAZIDIME - p. 241 91. CEFTAZIDIME/AVIBACTAM - p. 245 92. CEFTOBIPROLE MEDOCARIL - p. 249 93. CEFTOLOZANE/TAZOBACTAM - p. 252 94. CEFTRIAXONE SODIUM - p. 254 95. CEFUROXIME SODIUM - p. 258 96. CEMIPLIMAB-rwlc - p. 261 97. CENTRUROIDES (SCORPION) IMMUNE F(ab’)2 (EQUINE) INJECTION - p. 265 98. CETIRIZINE HYDROCHLORIDE - p. 265.e2 99. CETUXIMAB - p. 266 100. CHLORAMPHENICOL SODIUM SUCCINATE - p. 271 101. CHLOROTHIAZIDE SODIUM - p. 271.e3 102. CHLORPROMAZINE HYDROCHLORIDE - p. 273 103. USUAL DOSE - p. 274 104. PEDIATRIC DOSE - p. 274 105. DOSE ADJUSTMENTS - p. 274 106. DILUTION - p. 274 107. COMPATIBILITY - p. 274 108. RATE OF ADMINISTRATION - p. 274 109. ACTIONS - p. 274 110. INDICATIONS AND USES - p. 275 111. CONTRAINDICATIONS - p. 275 112. PRECAUTIONS - p. 275 113. DRUG/LAB INTERACTIONS - p. 276 114. SIDE EFFECTS - p. 276 115. ANTIDOTE - p. 276 116. CIPROFLOXACIN - p. 277 117. CISPLATIN - p. 283 118. CLEVIDIPINE BUTYRATE - p. 286 119. CLINDAMYCIN PHOSPHATE - p. 288 120. CLOFARABINE - p. 291 121. COAGULATION FACTOR VIIa (RECOMBINANT) RTS - p. 295 122. COAGULATION FACTOR X (HUMAN) - p. 298 123. COAGULATION FACTOR Xa (RECOMBINANT), INACTIVATED-zhzo - p. 301 124. COLISTIMETHATE SODIUM - p. 303 125. CONIVAPTAN HYDROCHLORIDE - p. 306 126. CONJUGATED ESTROGENS - p. 308 127. COPANLISIB - p. 313.e3 128. CORTICORELIN OVINE TRIFLUTATE - p. 313.e7 129. COSIBELIMAB - p. 313.e9 130. COSYNTROPIN - p. 312 131. CRIZANLIZUMAB-tmca INJECTION - p. 314 132. CROTALIDAE IMMUNE F(ab’)2 (EQUINE) - p. 314.e2 133. CYCLOPHOSPHAMIDE - p. 314.e4 134. CYCLOSPORINE - p. 319 135. CYSTEINE HYDROCHLORIDE - p. 323 136. CYTARABINE - p. 327 137. CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) * - p. 329 138. GENERIC DRUGS: D - p. e4 139. D - p. e4 140. DACARBAZINE - p. e4 141. DACTINOMYCIN - p. 333 142. DALBAVANCIN - p. 333.e3 143. DANTROLENE SODIUM - p. 335 144. DAPTOMYCIN - p. 338 145. DARATUMUMAB - p. 343 146. DARBEPOETIN ALFA - p. 343.e6 147. DAUNORUBICIN HYDROCHLORIDE ■ DAUNORUBICIN CITRATE LIPOSOMAL INJECTION - p. 349 148. DEFEROXAMINE MESYLATE - p. 353 149. DEFIBROTIDE - p. 353.e3 150. DELAFLOXACIN - p. 353.e6 151. DENILEUKIN DIFTITOX - p. 357 152. DESMOPRESSIN ACETATE - p. 357.e3 153. DEXAMETHASONE SODIUM PHOSPHATE - p. 360 154. DEXRAZOXANE - p. 365 155. DEXTRAN 1 - p. 368 156. DEXTRAN HIGH MOLECULAR WEIGHT - p. 368.e1 157. DEXTRAN LOW MOLECULAR WEIGHT - p. 370 158. DEXTROSE - p. 371 159. DIAZEPAM - p. 375 160. DIAZOXIDE - p. 378 161. Difelikefalin - p. 378.e2 162. DIGOXIN - p. 379 163. DIGOXIN IMMUNE FAB (OVINE) - p. 385 164. DIHYDROERGOTAMINE MESYLATE - p. 387 165. DILTIAZEM HYDROCHLORIDE - p. 389 166. DIMENHYDRINATE - p. 393 167. DINUTUXIMAB - p. 393.e2 168. DIPHENHYDRAMINE HYDROCHLORIDE - p. 398 169. DIPHTHERIA ANTITOXIN - p. 400 170. DIPYRIDAMOLE - p. 400.e2 171. DOBUTAMINE HYDROCHLORIDE - p. 402 172. DOCETAXEL - p. 405 173. USUAL DOSE - p. 406 174. DOSE ADJUSTMENTS - p. 407 175. DILUTION - p. 408 176. COMPATIBILITY - p. 409 177. RATE OF ADMINISTRATION - p. 409 178. ACTIONS - p. 409 179. INDICATIONS AND USES - p. 410 180. CONTRAINDICATIONS - p. 410 181. PRECAUTIONS - p. 410 182. DRUG/LAB INTERACTIONS - p. 412 183. SIDE EFFECTS - p. 412 184. ANTIDOTE - p. 413 185. Donanemab - p. 413 186. DOPAMINE HYDROCHLORIDE - p. 417 187. DOXAPRAM HYDROCHLORIDE - p. 421 188. DOXERCALCIFEROL - p. 421.e4 189. DOXORUBICIN HYDROCHLORIDE ■ DOXORUBICIN HYDROCHLORIDE LIPOSOMAL INJECTION - p. 424 190. DOXYCYCLINE HYCLATE - p. 431 191. DROPERIDOL - p. 434 192. DURVALUMAB - p. 434.e3 193. GENERIC DRUGS: E - p. e5 194. E - p. e5 195. GENERIC DRUGS: F - p. e6 196. F - p. e6 197. GENERIC DRUGS: G - p. e7 198. G - p. e7 199. GENERIC DRUGS: H - p. e8 200. H - p. e8 201. GENERIC DRUGS: I - p. e9 202. I - p. e9 203. IBALIZUMAB-uiyk - p. e9 204. IBANDRONATE SODIUM - p. 635 205. IBUPROFEN - p. 638 206. IBUPROFEN LYSINE - p. 642 207. IBUTILIDE FUMARATE - p. 644 208. IDARUBICIN HYDROCHLORIDE - p. 646 209. IDARUCIZUMAB - p. 649 210. IDURSULFASE - p. 651 211. IFOSFAMIDE - p. 651.e3 212. ILOPROST - p. 655 213. IMETELSTAT - p. 657 214. IMIGLUCERASE ■ VELAGLUCERASE ALFA - p. 659 215. IMIPENEM-CILASTATIN - p. 659.e4 216. IMIPENEM, CILASTATIN, AND RELEBACTAM - p. 663 217. IMMUNE GLOBULIN INTRAVENOUS - p. 667 218. INDOMETHACIN SODIUM - p. 676 219. INFLIXIMAB ■ INFLIXIMAB-dyyba ■ INFLIXIMAB-abdaa ■ INFLIXIMAB-axxqa ■ INFLIXIMAB-qbtxa - p. 678 220. INSULIN HUMAN ASPART or LISPRO or GLULISINE - p. 685 221. INOTUZUMAB OZOGAMICIN - p. 687 222. INSULIN HUMAN INJECTION (REGULAR) - p. 689.e5 223. INTERFERON ALFA-2b, RECOMBINANT - p. 693 224. IPILIMUMAB - p. 693.e4 225. IRINOTECAN HYDROCHLORIDE ■ IRINOTECAN LIPOSOME INJECTION - p. 693.e10 226. IRON DEXTRAN INJECTION - p. 703 227. IRON SUCROSE - p. 705 228. ISATUXIMAB - p. 709 229. USUAL DOSE - p. 709 230. PEDIATRIC DOSE - p. 709 231. DOSE ADJUSTMENTS - p. 709 232. DILUTION - p. 709 233. COMPATIBILITY - p. 710 234. RATE OF ADMINISTRATION - p. 710 235. ACTIONS - p. 710 236. INDICATIONS AND USES - p. 710 237. CONTRAINDICATIONS - p. 710 238. PRECAUTIONS - p. 710 239. DRUG/LAB INTERACTIONS - p. 710 240. SIDE EFFECTS - p. 710 241. ANTIDOTE - p. 710 242. ISAVUCONAZONIUM SULFATE - p. 710 243. ISOPROTERENOL HYDROCHLORIDE - p. 713 244. IXABEPILONE - p. 717 245. GENERIC DRUGS: K - p. e10 246. K - p. e10 247. GENERIC DRUGS: L - p. e11 248. L - p. e11 249. GENERIC DRUGS: M - p. e12 250. M - p. e12 251. MAGNESIUM SULFATE - p. e12 252. MANNITOL - p. 769 253. MECHLORETHAMINE HYDROCHLORIDE - p. 773 254. MELOXICAM INJECTION - p. 773.e2 255. MEPERIDINE HYDROCHLORIDE - p. 776 256. MEROPENEM - p. 781 257. MEROPENEM AND VABORBACTAM FOR INJECTION - p. 785 258. MESNA - p. 788 259. METHADONE HYDROCHLORIDE - p. 791 260. METHOCARBAMOL - p. 799 261. METHOTREXATE SODIUM - p. 793 262. METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA - p. 805 263. METHYLENE BLUE - p. 805.e5 264. METHYLERGONOVINE MALEATE - p. 805.e8 265. METHYLPREDNISOLONE SODIUM SUCCINATE - p. 807 266. METOCLOPRAMIDE HYDROCHLORIDE - p. 812 267. METOPROLOL TARTRATE - p. 815 268. METRONIDAZOLE HYDROCHLORIDE - p. 818 269. MICAFUNGIN SODIUM - p. 822 270. MILRINONE LACTATE - p. 826 271. MINOCYCLINE HYDROCHLORIDE - p. 829 272. MITOMYCIN - p. 829.e3 273. MITOXANTRONE HYDROCHLORIDE - p. 832 274. MOGAMULIZUMAB-kpkc - p. 835 275. MORPHINE SULFATE - p. 835.e3 276. MOSUNETUZUMAB - p. 840 277. MOXIFLOXACIN HYDROCHLORIDE - p. 846 278. MULTIVITAMIN INFUSION - p. 851 279. USUAL DOSE - p. 852 280. PEDIATRIC DOSE - p. 852 281. DILUTION - p. 852 282. COMPATIBILITY - p. 852 283. RATE OF ADMINISTRATION - p. 853 284. ACTIONS - p. 853 285. INDICATIONS AND USES - p. 853 286. CONTRAINDICATIONS - p. 853 287. PRECAUTIONS - p. 853 288. DRUG/LAB INTERACTIONS - p. 854 289. SIDE EFFECTS - p. 854 290. ANTIDOTE - p. 854 291. MYCOPHENOLATE MOFETIL HYDROCHLORIDE - p. 854 292. GENERIC DRUGS: N - p. e13 293. N - p. e13 294. GENERIC DRUGS: O - p. e14 295. O - p. e14 296. GENERIC DRUGS: P - p. e15 297. P - p. e15 298. PACLITAXEL ■ PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) - p. e15 299. PALIFERMIN - p. 938 300. PALONOSETRON - p. 941 301. PAMIDRONATE DISODIUM - p. 943 302. PANITUMUMAB - p. 947 303. PANTOPRAZOLE SODIUM - p. 951 304. PAPAVERINE HYDROCHLORIDE - p. 954 305. PARICALCITOL - p. 956 306. PEGASPARGASE ■ ASPARAGINASE Erwinia chrysanthemi - p. 959 307. PEGLOTICASE - p. 959.e5 308. PEMBROLIZUMAB - p. 962 309. PEMETREXED - p. 970 310. PENICILLIN G AQUEOUS - p. 974 311. PENTAMIDINE ISETHIONATE - p. 978 312. PENTETATE CALCIUM TRISODIUM INJECTION ■ PENTETATE ZINC TRISODIUM INJECTION - p. 979 313. PENTOBARBITAL SODIUM - p. 979.e4 314. PENTOSTATIN - p. 981 315. PERAMIVIR - p. 984 316. PERTUZUMAB - p. 986 317. PHENOBARBITAL SODIUM - p. 991 318. PHENTOLAMINE MESYLATE - p. 993 319. PHENYLEPHRINE HYDROCHLORIDE - p. 993.e2 320. PHENYTOIN SODIUM - p. 995 321. PHOSPHATE - p. 1000 322. PHYSOSTIGMINE SALICYLATE - p. 1001 323. PHYTONADIONE - p. 1003 324. PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM - p. 1005 325. PLASMA PROTEIN FRACTION - p. 1009 326. POLATUZUMAB VEDOTIN-piiq - p. 1009.e2 327. USUAL DOSE - p. 1010 328. DOSE ADJUSTMENTS - p. 1010 329. DILUTION - p. 1010 330. COMPATIBILITY - p. 1012 331. RATE OF ADMINISTRATION - p. 1012 332. ACTIONS - p. 1012 333. INDICATIONS AND USES - p. 1012 334. CONTRAINDICATIONS - p. 1012 335. PRECAUTIONS - p. 1012 336. DRUG/LAB INTERACTIONS - p. 1014 337. SIDE EFFECTS - p. 1014 338. ANTIDOTE - p. 1014 339. POOLED PLASMA (HUMAN) - p. 1014 340. PORFIMER SODIUM - p. 1014.e3 341. POSACONAZOLE - p. 1019 342. POTASSIUM ACETATE AND POTASSIUM CHLORIDE - p. 1023 343. PRALATREXATE - p. 1027 344. PRALIDOXIME CHLORIDE - p. 1031 345. PROCAINAMIDE HYDROCHLORIDE - p. 1031.e3 346. PROCHLORPERAZINE EDISYLATE - p. 1034 347. PROMETHAZINE HYDROCHLORIDE - p. 1037 348. PROPOFOL INJECTION - p. 1040 349. PROPRANOLOL HYDROCHLORIDE - p. 1045 350. PROTAMINE SULFATE - p. 1049 351. PROTEIN AMINO ACIDS, DEXTROSE, FAT EMULSION, AND ELECTROLYTES - p. 1051 352. PROTEIN (AMINO ACID) PRODUCTS - p. 1056 353. PROTEIN C CONCENTRATE (HUMAN) - p. 1056.e5 354. PROTHROMBIN COMPLEX CONCENTRATE (HUMAN) - p. 1056.e8 355. PYRIDOSTIGMINE BROMIDE - p. 1059 356. PYRIDOXINE HYDROCHLORIDE - p. 1059.e2 357. GENERIC DRUGS: R - p. e17 358. R - p. e17 359. GENERIC DRUGS: S - p. e18 360. S - p. e18 361. GENERIC DRUGS: T - p. e19 362. T - p. e19 363. GENERIC DRUGS: V - p. e20 364. V - p. e20 365. GENERIC DRUGS: Z - p. e21 366. Z - p. e21 367. Appendix A. Recommendations for the Safe Use and Handling of Cytotoxic Drugs - p. 1253.e1 368. Appendix B. FDA Pregnancy Categories - p. 1253.e2 369. Appendix C. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) - p. 1253.e3 370. Appendix D. Information for Patients Receiving Immunosuppressive Agents - p. 1253.e4 371. Appendix E. Recently Approved Drugs - p. 1253.e5 372. Index - p. 1254 373. Solution Compatibility Chart - p. ES3
